Skip to main content

ORIGINAL RESEARCH article

Front. Med.

Sec. Pulmonary Medicine

Volume 12 - 2025 | doi: 10.3389/fmed.2025.1553188

This article is part of the Research Topic Cholesterol, inflammation and immunity View all 4 articles

Lymphocyte-to-high-density lipoprotein ratio and Mortality in Asthma Patients: A Novel Immunoinflammatory Biomarker with Nonlinear Association

Provisionally accepted
lei Tu Tian lei Tu Tian 1*Ling Mei Xie Ling Mei Xie 2
  • 1 china, Department of Respiratory and Critical Care Medicine, The Affiliated Bozhou Hospital of Anhui Medical University, Bozhou, 236800, Anhui, China, China
  • 2 Bengbu Medical University Graduate School, Bengbu, Anhui Province, China

The final, formatted version of the article will be published soon.

    Background: The lymphocyte-to-high-density lipoprotein ratio (LHR), a novel biomarker reflecting systemic inflammation and immune status, has been widely studied in various diseases. However, its association with mortality risk among asthma patients remains unexplored.Methods: This study utilized data from the National Health and Nutrition Examination Survey (NHANES) spanning 1999–2018, including 5,323 adult asthma patients. Mortality outcomes were ascertained through linkage with the National Death Index (NDI) up to December 31, 2019. Cox proportional hazards models and Fine-Gray competing risk models were employed to examine the association between LHR and mortality risks. Dose-response relationships were assessed using restricted cubic spline analyses.Results: Over a mean follow-up period of 106.95 months, 724 all-cause deaths (13.6%) were recorded. After multivariable adjustment, a one-unit increase in log-transformed LHR was associated with reduced risks of mortality: 18% for all-cause (HR = 0.82, 95% CI: 0.74–0.91), 21% for cardiovascular disease (CVD) (HR = 0.79, 95% CI: 0.65–0.96), and 41% for chronic lower respiratory disease (CLRD) (HR = 0.59, 95% CI: 0.45–0.77). Restricted cubic spline analyses showed an L-shaped association of LHR with all-cause and CLRD mortality, with inflection points at 1.78 and 1.52, respectively. For CVD mortality, a linear association was observed. Competing risk models further confirmed the association of LHR with reduced CLRD mortality (SHR = 0.64, 95% CI: 0.46–0.88), while the association with CVD mortality was no longer significant (SHR = 0.85, 95% CI: 0.70–1.03).Conclusion: LHR is nonlinearly associated with all-cause and CLRD mortality and shows a significant inverse association with CLRD mortality risk. These findings were further validated using competing risk models, highlighting the robustness of the results.

    Keywords: Lymphocyte-to-high-density lipoprotein ratio (LHR), Asthma, Mortality, Competing risk analysis, NHANES

    Received: 30 Dec 2024; Accepted: 11 Mar 2025.

    Copyright: © 2025 Tian and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: lei Tu Tian, china, Department of Respiratory and Critical Care Medicine, The Affiliated Bozhou Hospital of Anhui Medical University, Bozhou, 236800, Anhui, China, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    95% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more